License To Fill: Pipeline Top AstraZeneca Priority Under Brennan
Executive Summary
AstraZeneca's plans to bolster its product pipeline include further efforts to tap external technology sources, according to CEO David Brennan
You may also be interested in...
Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows
AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space
Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows
AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space
AstraZeneca Clinical Setbacks Add To Pipeline Woes
AstraZeneca is terminating development of two Phase III clinical trial programs after they failed to meet their primary endpoints, dealing a blow to the U.K. drug maker's already troubled pipeline